Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide in STEMI
NCT00568061Phase 2Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jun 2006
- Primary completion
- Jun 2008
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in ST elevation myocardial infarction (STEMI) comparing Inhaled Nitric Oxide with Placebo (2 arms). Primary endpoint: Mean Percent of Myocardial Infarction Size to the Fraction of Left Ventricular Size. Started Jun 2006; status: terminated.
02
Drugs
nitric oxide
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT00568061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00568061.